Network Meta-analysis of Yiqi Huoxue Chinese patent medicine for coronary heart disease with angina pectoris.
10.19540/j.cnki.cjcmm.20190114.001
- Author:
Zhao-Chen JI
1
;
Hai-Yin HU
1
;
Feng-Wen YANG
1
;
Li-Shuang ZHANG
1
;
Xin-Yao JIN
1
;
Hu-Cheng WANG
1
;
Wen-Tai PANG
1
;
Nan LI
1
;
Ke-Yi WANG
1
;
Jun-Hua ZHANG
1
Author Information
1. Evidence-based Medicine Center,Tianjin University of Traditional Chinese Medicine Tianjin 300193,China.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
Yiqi Huoxue;
angina pectoris;
coronary heart disease;
network Meta-analysis
- MeSH:
Angina Pectoris;
drug therapy;
China;
Coronary Disease;
drug therapy;
Drugs, Chinese Herbal;
therapeutic use;
Humans;
Network Meta-Analysis;
Nonprescription Drugs;
Randomized Controlled Trials as Topic
- From:
China Journal of Chinese Materia Medica
2019;44(9):1927-1937
- CountryChina
- Language:Chinese
-
Abstract:
To assess the clinical efficacy of Yiqi Huoxue Chinese patent medicine for coronary heart disease with angina pectoris by using network Meta-analysis method. The relative randomized controlled trials( RCTs) of Yiqi Huoxue Chinese patent medicine for coronary heart disease with angina pectoris were retrieved from China National Knowledge Infrastructure( CNKI),Wan Fang,VIP and Chinese Biomedical Literature Database( CBM) in July 2018. Two researchers independently completed the literature screening,data extraction and quality evaluation according to the pre-determined inclusion and exclusion criteria,and the results were cross-checked.The data were analyzed by Win Bugs,and STATA software was used for plotting. Finally,114 RCTs were included,involving 7 Yiqi Huoxue Chinese patent medicines and 11 775 patients. Network Meta-analysis showed that the total effective rate for improvement in AP symptoms had 7 direct comparisons and 21 indirect comparisons,8 of which were statistically significant. The ECG improvement had 7 direct comparisons and 21 indirect comparisons,7 of which were statistically significant. In terms of the total effective rate of improvement in AP symptoms,the order of efficacy was as follows: Shensong Yangxin Capsules > Shexiang Baoxin Pills > Qishen Yiqi Dropping Pills > Tongxinluo Capsules > Wenxin Granules > Qishen Capsules > Naoxintong Capsules. In terms of ECG improvement,the order of efficacy was as follows: Shexiang Baoxin Pills > Tongxinluo Capsules > Naoxintong Capsules > Qishen Yiqi Dropping Pills> Wenxin Granules > Shensong Yangxin Capsules > Qishen Capsules. The results showed that Shensong Yangxin Capsules and Shexiang Baoxin Pills had certain advantages in the treatment of coronary heart disease with angina pectoris. Due to the small sample size,more studies were required to further verify the evidences.
